BlossomHill Therapeutics, Inc. Common Stock Cash Flow Conversion Efficiency
BlossomHill Therapeutics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, BlossomHill Therapeutics, Inc. Common Stock (BLSM) has a cash flow conversion efficiency ratio of 0.138x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.94 Million) by net assets ($-152.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
Cash flow conversion efficiency of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. This chart illustrates how BlossomHill Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for BlossomHill Therapeutics, Inc. Common St for real-time trading data and today's change.
BlossomHill Therapeutics, Inc. Common Stock Cash Flow Conversion Ratio Explained
BlossomHill Therapeutics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BlossomHill Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BlossomHill Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see BlossomHill Therapeutics, Inc. Common St market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Digital Network S.A.
WAR:DIG
|
0.143x |
|
Avidia Bancorp, Inc.
NYSE:AVBC
|
0.023x |
|
KT Submarine Co. Ltd
KQ:060370
|
0.022x |
|
Moso Power Supply Technology Co Ltd
SHE:002660
|
0.069x |
|
Korea Petro Chemical Ind
KO:006650
|
0.012x |
|
Gran Tierra Energy Inc
TO:GTE
|
0.426x |
|
Sofwave Medical Ltd
TA:SOFW
|
-0.014x |
|
Alpha Hpa Ltd
AU:A4N
|
-0.030x |
Annual Cash Flow Conversion Efficiency for BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. Review how financially flexible is BlossomHill Therapeutics, Inc. Common St to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-131.73 Million | $-46.92 Million | 0.356x | -17.36% |
| 2024-12-31 | $-72.88 Million | $-31.42 Million | 0.431x | -- |
About BlossomHill Therapeutics, Inc. Common Stock
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients w… Read more